DalsnaFinance

Gain Therapeutics $GANX

Health Care

Maryland
Create a scorecard
$1.69
-0.02 (-1.17%)
As of Oct 5, 2026, 5:17 PM EDT · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 5, 2026, the first target we tracked for GANX.

Gain Therapeutics (GANX) is trading down at $1.69 (-1.17%), as of the latest quote. It operates in the Health Care sector.

IPO: March 18, 2021 · $11.00 offering · NASDAQ · View IPO details →

Analyst price targets on GANX

One firm's current price target on Gain Therapeutics: $5 — 196% above the current $1.69. Each is tracked to its date and scored the same way a member's call is.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Gain Therapeutics revenue & net income history (FY2020–FY2025)

RevenueNet income
$165.0K−$11.1M−$22.3MFY2020 revenue: $28.9KFY2020 net income: −$3.58M'20FY2021 revenue: $165.0KFY2021 net income: −$13.9M'21FY2022 revenue: $140.1KFY2022 net income: −$17.6M'22FY2023 revenue: $55.2KFY2023 net income: −$22.3M'23FY2024 net income: −$20.4M'24FY2025 net income: −$20.2M'25
Gain Therapeutics annual financial statements
FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$28.9K$165.0K$140.1K$55.2K——
Growth (year over year)—+471.3%−15.1%−60.6%——
Operating income−$3.48M−$13.8M−$17.8M−$22.3M−$20.4M−$18.7M
Operating margin−12047.5%−8379.8%−12688.1%−40328.3%——
Net income−$3.58M−$13.9M−$17.6M−$22.3M−$20.4M−$20.2M
Net margin−12387.7%−8418.9%−12555.1%−40354.3%——
EPS (diluted)−$1.33−$1.37−$1.48−$1.71−$0.89−$0.61
Balance sheet
Cash and equivalents$7.49M$36.9M$7.31M$11.8M$10.4M$20.8M
Total assets$9.60M$39.0M$24.1M$18.6M$12.1M$22.8M
Total liabilities$3.40M$4.17M$5.22M$6.03M$4.78M$4.25M
Long-term debt$715.7K$590.5K$495.3K$449.1K$328.3K$300.1K
Shareholders' equity$6.20M$34.8M$18.9M$12.6M$7.34M$18.6M
Cash flow
Operating cash flow−$3.24M−$12.4M−$14.7M−$18.9M−$18.9M−$18.5M
Capital expenditure$20.8K$94.2K$119.0K$15.4K$22.5K—
Free cash flow−$3.26M−$12.5M−$14.8M−$18.9M−$18.9M—

From Gain Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Gain Therapeutics

Headquarters
Bethesda, Maryland From SEC filings, Oct 2026

Recent News (1)

Other Health Care companies to compare with GANX

Browse all companies →